CLINICAL_TRIALS
trial_result
· 2009-12-21
Clinical Trial Update: SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma [Phase 2]
Summary
Pfizer-sponsored Phase 2 study of SU011248 for bevacizumab-refractory metastatic renal cell carcinoma has completed with results posted in 2009.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2009-12-21